A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells
Science Advances · 24.05.2024 · 10 (21)
DOI: 10.1126/sciadv.adj1564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 24.05.2024. Verfasst von Daria Bulanova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Casein Kinase II, Retinoblastoma Binding Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Resistance to therapy commonly develops in patients with high-grade serous ovarian carcinoma (HGSC) and triple-negative breast cancer (TNBC), urging the search for improved therapeutic combinations and their predictive biomarkers. Starting from a CRISPR knockout screen, we identified that loss of RB1 in TNBC or HGSC cells generates a synthetic lethal dependency on casein kinase 2 (CK2) for surviving the treatment with replication-perturbing therapeutics such as carboplatin, gemcitabine, or PARP inhibitors. CK2 inhibition in RB1-deficient cells resulted in the degradation of another RB family cell cycle regulator, p130, which led to S phase accumulation, micronuclei formation, and accelerated PARP inhibition–induced aneuploidy and mitotic cell death. CK2 inhibition was also effective in primary patient-derived cells. It selectively prevented the regrowth of RB1-deficient patient HGSC organoids after treatment with carboplatin or niraparib. As about 25% of HGSCs and 40% of TNBCs have lost RB1 expression, CK2 inhibition is a promising approach to overcome resistance to standard therapeutics in large strata of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
- Institute for Molecular Medicine Finland, Helsinki Institute for Life Sciences, University of Helsinki, Helsinki, Finland.
- Research Program in Systems Oncology (ONCOSYS), University of Helsinki, Helsinki, Finland.
- Finnish Red Cross Blood Service, Helsinki, Finland.
- Department of Obstetrics and Gynecology, Turku University Hospital and University of Turku, Turku, Finland.
- Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Daria Bulanova, Yevhen Akimov, Wojciech Senkowski, Jaana Oikkonen, Laura Gall-Mas, Sanna Timonen, Johanna Hynninen, Sampsa Hautaniemi, Tero Aittokallio, Krister Wennerberg
Zitieren
APA
Bulanova, D., Akimov, Y., Senkowski, W., Oikkonen, J., Gall-Mas, L., Timonen, S., Elmadani, M., Hynninen, J., Hautaniemi, S., Aittokallio, T., & Wennerberg, K. (2024). A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Science Advances, 10(21). https://doi.org/10.1126/sciadv.adj1564
Vancouver
Bulanova D, Akimov Y, Senkowski W, Oikkonen J, Gall-Mas L, Timonen S, et al. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Science Advances. 2024;10(21). doi:10.1126/sciadv.adj1564
BibTeX
@article{Bulanova2024,
author = {Bulanova, Daria and Akimov, Yevhen and Senkowski, Wojciech and Oikkonen, Jaana and Gall-Mas, Laura and Timonen, Sanna and Elmadani, Manar and Hynninen, Johanna and Hautaniemi, Sampsa and Aittokallio, Tero and Wennerberg, Krister},
title = {A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {21},
doi = {10.1126/sciadv.adj1564}
}
EUVIMED